IDEAS home Printed from https://ideas.repec.org/h/spr/sprchp/978-3-030-31503-0_14.html
   My bibliography  Save this book chapter

Phase II Dose Finding

In: Statistical Methods in Biomarker and Early Clinical Development

Author

Listed:
  • Qiqi Deng

    (Boehringer-Ingelheim Pharmaceuticals, Inc., Department of Biostatistics and Data Sciences)

  • Naitee Ting

    (Boehringer-Ingelheim Pharmaceuticals, Inc., Department of Biostatistics and Data Sciences)

Abstract

In the process of new drug discovery and development, understanding the dose–response relationship is one of the most challenging tasks. It is also critical to identify the right range of doses in early stages of clinical development so that Phase III trials can be designed to confirm some doses within this range. Usually at the beginning of Phase II, there is not a lot of available information to help guide the study design. At this stage, Phase II clinical studies are needed to establish proof-of-concept (PoC), to identify a set of potentially effective and safe doses, and to estimate dose–response relationships. Challenges in designing these studies include: selection of the dose frequency and the dose range, choice of clinical endpoints or biomarkers, and use of control(s), among others. Consequences of bad Phase II study designs may lead to the delay of the entire clinical development program or the wastage of R&D investment. In fact, the entire drug development process can be viewed as a scientific search of right doses—starting from discovery, up to clinical Phases I, II, III, and IV—is a process to find one or a few efficacious and safe doses.

Suggested Citation

  • Qiqi Deng & Naitee Ting, 2019. "Phase II Dose Finding," Springer Books, in: Liang Fang & Cheng Su (ed.), Statistical Methods in Biomarker and Early Clinical Development, pages 301-320, Springer.
    • Handle: RePEc:spr:sprchp:978-3-030-31503-0_14
    DOI: 10.1007/978-3-030-31503-0_14
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a
    for a similarly titled item that would be available.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:sprchp:978-3-030-31503-0_14. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.